Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.51 |
| ▸ | F10 | P00742 | 3/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963940 | 0.88 | F10 (0.52) | CCR2F10F2SMN1; SMN2RAB9A | |
| SCHEMBL3969267 | 0.86 | PTGS2 (0.57) | CCR2PTGS2F10F2LMNA | |
| SCHEMBL3968297 | 0.84 | CCR2 (0.50) | CCR2F10F2SMN1; SMN2RAB9A | |
| SCHEMBL3963966 | 0.82 | F10 (0.62) | CCR2F10F2SMN1; SMN2RAB9A | |
| SCHEMBL1675245 | 0.81 | F10 (0.78) | F10F2 | |
| SCHEMBL5618711 | 0.77 | F10 (0.47) | CCR2F10F2SMN1; SMN2RAB9A | |
| SCHEMBL16211084 | 0.77 | CCR2 (0.81) | CCR2PTGS2 | |
| SCHEMBL4879621 | 0.76 | F10 (0.69) | F10F2SMN1; SMN2RAB9APOLB | |
| SCHEMBL4879163 | 0.76 | F10 (0.58) | F10F2SMN1; SMN2RAB9APOLB | |
| SCHEMBL15911364 | 0.74 | F10 (0.61) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | claimed |
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | claimed |
| JP-2005514365-A | — | — | 2005-05-19 | — | — | JP | claimed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | claimed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | claimed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | claimed |
| EP-1683825-B1 | HIGHLY MOISTUREPROOF FILM AND PROCESS FOR PRODUCING THE SAME | TOPPAN PRINTING CO LTD (JP) | 2016-08-17 | — | — | EP | disclosed |
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-7501176-B2 | Highly moisture proof film and method of manufacturing the same | KUREHA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20070134507-A1 | Highly moisture proof film and method of manufacturing the same | TOPPAN PRINTING CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1683825-A1 | HIGHLY MOISTUREPROOF FILM AND PROCESS FOR PRODUCING THE SAME | Kureha Corporation (JP) | 2006-07-26 | — | — | EP | disclosed |
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | disclosed |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | F12, F5, F2 | CCR2 1071/4885PTGS2 1300/4885F10 10/4885 |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | F5, F12, F2 | CCR2 851/4885PTGS2 708/4885F10 9/4885 |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | F12, F5, F2 | CCR2 1193/4885PTGS2 1393/4885F10 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.